Recent Quotes
My Watchlist
Indicators
Hydroworld Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Myriad Genetics, Inc. - Common Stock (NQ:MYGN)

6.580 +0.120 (+1.86%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Myriad Genetics, Inc. - Common Stock

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Where Myriad Genetics Stands With Analysts
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 23, 2023
 
Via Benzinga
Lilium, Myriad Genetics And Other Big Stocks Moving Higher In Tuesday's Pre-Market Session
U.S. stock futures traded lower this morning. Here are some big stocks recording gains in today’s pre-market trading session. 
Via Benzinga
Exact Sciences Serves Investors Exactly What They Wished For
Diagnostic and cancer test products provider Exact Sciences Corp. (NASDAQ: EXAS) saw its shares spike over 17% on its Q1 2023 earnings results. The 
Via MarketBeat
Where Myriad Genetics Stands With Analysts
 
Via Benzinga
Earnings Preview For Myriad Genetics
 
Via Benzinga
Myriad Genetics Earns 2023 Great Place to Work Certification™
From Myriad Genetics, Inc.
Via GlobeNewswire
Why Atlassian Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers 
Via Benzinga
Myriad Genetics Reports First Quarter 2023 Financial Results; Achieves 10% Revenue Growth Year-Over-Year, the Second Consecutive Quarter of Double-Digit Year-Over-Year Revenue Growth; Raises Mid-Point of 2023 Revenue Guidance Range
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics to Participate in BofA Securities Healthcare Conference
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics to Release First Quarter Financial Results on May 3, 2023
From Myriad Genetics, Inc.
Via GlobeNewswire
77% of Americans have used addictive behaviors or unhealthy coping mechanisms to manage their mental health, according to Myriad Genetics nationwide survey
Medication failure leads 45% of respondents with depression and/or anxiety to turn to unhealthy coping mechanisms 
From Myriad Genetics, Inc.
Via GlobeNewswire
Intermountain Precision Genomics and Myriad Genetics Now Offer Solid Tumor Testing in All 50 States
About Intermountain Health Headquartered in Utah with locations in seven states and additional operations across the western U.S., www.intermountainhealth.org is a nonprofit system of 33 hospitals, 385... 
Via PRUnderground
Myriad Genetics and Intermountain Precision Genomics Now Offer Solid Tumor Testing in All 50 States with Latest NY State Certification
Intermountain Precision Genomics Laboratory receives certification from NYS Department of Health Clinical Laboratory Evaluation Program 
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics and SimonMed® Imaging Collaborate to Advance Precision Medicine with New Genetic Risk Assessment Program
New program will increase access to affordable genetic testing while also helping to identify and elevate high-risk patient care 
From Myriad Genetics, Inc.
Via GlobeNewswire
The 3 Best CRISPR Stocks to Buy Now Before They Skyrocket
Moving forward, CRISPR could revolutionize the way we treat thousands of diseases. The best CRISPR stocks will profit from it. 
Via InvestorPlace
Illumina and Myriad Genetics expand partnership to broaden access to HRD testing in the United States
Strategic partnership offers a unique combination of diagnostic development and commercialization capabilities to the pharmaceutical industry 
From Myriad Genetics, Inc.
Via GlobeNewswire
Why Novavax Shares Are Trading Lower By Around 28%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers Reata Pharmaceuticals Inc (NASDAQ: RETA) shares jumped 171.5% to $84.67 after the company reported the FDA approval of SKYCLARYS for patients with Friedreich's Ataxia. 
Via Benzinga
3D Systems, CarGurus, Sarepta Therapeutics And Other Big Stocks Moving Higher On Wednesday
U.S. stocks traded lower, with the Dow Jones dropping around 80 points on Wednesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Myriad Genetics Applauds New Expanded Carrier Screening Practice Guidelines from NSGC
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Reports Fourth Quarter Financial Results; Fourth Quarter Revenue of $177.8 Million Grew 11% Year-Over-Year Driven by 16% Growth in Hereditary Cancer Volumes and 23% Growth in GeneSight® Volumes
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics to Release Fourth-Quarter Financial Results on Feb. 28, 2023
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics to Participate in Upcoming Healthcare Conferences
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Highlights 2022 Research Findings that Help Advance More Accessible and Equitable Genetic Testing
From Myriad Genetics, Inc.
Via GlobeNewswire
3 Small Caps That Have Big Upside
If market sentiment stays bullish, small caps with depressed shares prices and valuation could turn into big-time outperformers. 
Via MarketBeat
Topics Economy
3 Gene Editing Stocks With the Best Long-Term Potential
These gene editing stocks are likely to deliver massive gains ahead in the fast-evolving biotech space 
Via InvestorPlace
Insiders Selling DocuSign, Adobe And 2 Other Stocks
The Nasdaq settled higher by 2% on Monday. Investors, meanwhile, focused on some notable insider trades. 
Via Benzinga
Raymond James Upgrades Natera & Myriad Genetics, While Downgrading This Stock
 
Via Benzinga
Myriad Genetics Applauds New Guidelines Recommending Screening for Chromosomal Abnormalities
From Myriad Genetics, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For January 18, 2023
 
Via Benzinga
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.